• A Mothes, S Léotard, I Nicolle, A Smets, D Chirio, C Rotomondo, F Tiger, P Del Giudice, C Perrin, D Néri, C Foucault, M Della Guardia, H Hyvernat, P-M Roger, and Réseau Infectio-PACA-Est.
• Service d'infectiologie, centre hospitalier de Draguignan, 83300 Draguignan, France.
• Med Mal Infect. 2016 Oct 1; 46 (7): 365-371.

BackgroundThe use of rapid microbiological tests is supported by antimicrobial stewardship policies. Targeted antibiotic therapy (TAT) for community-acquired pneumonia (CAP) with positive urinary antigen test (UAT) has been associated with a favorable impact on outcome. We aimed to determine the factors associated with TAT prescription.Patients And MethodsWe conducted a retrospective multicenter study including all patients presenting with CAP and positive UAT for Streptococcus pneumoniae or Legionella pneumophila from January 2010 to December 2013. Patients presenting with aspiration pneumonia, coinfection, and neutropenia were excluded. CAP severity was assessed using the Pneumonia Severity Index (PSI). TAT was defined as the administration of amoxicillin for pneumococcal infection and either macrolides or fluoroquinolones (inactive against S. pneumoniae) for Legionella infection.ResultsA total of 861 patients were included, including 687 pneumococcal infections and 174 legionellosis from eight facilities and 37 medical departments. TAT was prescribed to 273 patients (32%). Four factors were found independently associated with a lower rate of TAT: a PSI score≥4 (OR 0.37), Hospital A (OR 0.41), hospitalization in the intensive care unit (OR 0.44), and cardiac comorbidities (OR 0.60). Four other factors were associated with a high rate of TAT: positive blood culture for S. pneumoniae (OR 2.32), Hospitals B (OR 2.34), E (OR 2.68), and H (OR 9.32).ConclusionTAT in CAP with positive UAT was related to the hospitals as well as to patient characteristics.Copyright © 2016 Elsevier Masson SAS. All rights reserved.

41 keywords...

hide…